Brief: Antengene Announces Research Collaboration With Celularity To Evaluate Potential Therapeutic Synergy Of Combining Antengene's Best-In-Class Bispecific Antibody With Celularity's Natural Killer Cell Platform
19/07/2022 11:15
July 19 (Reuters) - Antengene Corporation Ltd 6996.HK :
* ANTENGENE ANNOUNCES RESEARCH COLLABORATION WITH CELULARITY
TO
EVALUATE POTENTIAL THERAPEUTIC SYNERGY OF COMBINING ANTENGENE'S
BEST-IN-CLASS BISPECIFIC ANTIBODY WITH CELULARITY'S NATURAL
KILLER CELL PLATFORM
Source text for Eikon: ID:nPn5HDgSla
Further company coverage: 6996.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Antengene
See all newsBiotech firm Antengene's H1 revenue jumps on licensing deals
Brief: Antengene Corp Expects HY Profit Of RMB195 MLN-RMB238 MLN
Brief: Antengene Corp Receives Initial $60 Million Upfront Payment From UCB
Brief: Antengene Corp Intends To Repurchase Up To 67.92 Million Shares
Brief: Antengene Corp Enters Exclusive License Agreement With K2 Therapeutics For Atg-106